Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polyclonal antibody stimulator - Cancer Advances

Next Previous
X
Search
Drug Profile

Polyclonal antibody stimulator - Cancer Advances

Alternative Names: Anti-gastrin 17 immunogen; G17DT; Gastrimmune; Gastrin 17 diphtheria toxoid conjugate; Gastrin-17 vaccine; Gastrin-17 vaccine - Aphton; Insegia; PAS

Latest Information Update: 01 Mar 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphton Corporation
  • Developer Cancer Advances
  • Class Antiulcers; Cancer vaccines; Immunotherapies; Peptide hormones
  • Mechanism of Action Gastrin 17 inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Gastric cancer; Pancreatic cancer
  • Phase II Colorectal cancer; Gastro-oesophageal reflux

Most Recent Events

  • 28 Feb 2023 Cancer Advances has patent protection for Polyclonal antibody stimulator in USA
  • 06 Dec 2021 Pharmacodynamics data from a preclinical trial in Gastric cancer released by Cancer Advances
  • 24 Aug 2021 Cancer Advances plans to seek approval for Gastric cancer and Pancreatic cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top